Program
TNX-1500
A development code.
Its studies are led by Tonix Pharmaceuticals.
Furthest: phase 1, since Mar 10, 20261 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tonix Pharmaceuticals | 10 open or running | phase 1since Mar 10, 2026 | Mar 10, 2026 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 10, 2026First study: phase 1 study in Phase 1 First-in-human Study Involving Healthy SubjectsFirst studyNCT07473752 · 26 enrolled · United States
TargetBeta
CD40LG →read by rule
“The primary objective is to investigate the safety of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.”study text, by rule · the study
Other programs on CD40LG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| frexalimab | Sanofi | phase 3 | 11 |
| dazodalibeprule | Amgen | phase 3 | 9 |
| dapirolizumab pegolrule | UCB | phase 3 | 8 |
| tegoprubartrule | eledon-pharmaceuticals | phase 3 | 8 |
| ravagalimabrule | AbbVie | phase 2 | 4 |
| OPT101rule | op-t-llc | phase 2 | 4 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07473752Phase 1 First-in-human Study Involving Healthy Subjects · United States | 1 | Completed | Feb 22, 2024 | 26 |
How it is read
Names in the registry
- “TNX-1500”, 1 entry
Codes read as this program: TNX1500.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.